|Bid||6.21 x 1800|
|Ask||6.60 x 900|
|Day's Range||6.11 - 6.49|
|52 Week Range||1.93 - 8.56|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.70|
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
The shares lost about half of their value after the company disclosed disappointing trial results for a gene therapy meant to cure Duchenne muscular dystrophy.
The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.